Enovis Corporation ENOV

Full chart Compare
Set alert

Price alert · ENOV

All alert types
24.23 USD +3.34 (+15.97%)

Nov 4, 2026, 2:51 PM EST

21.78 Day range 24.61
16.70 52-week range 32.41
YTD
-9.06%
1 year
-22.95%
Market cap
1.40B
Revenue (ttm)
2.30B
Profit margin
-47.97%
EPS (ttm)
-19.23
Shares out
57.67M
Forward P/E
5.89
YTD return
-9.06%
1-year return
-22.95%
Volume
2.27M
Avg volume
1.59M
Open
21.77
Previous close
20.89
Day's range
21.78 – 24.61
52-week range
16.70 – 32.41
Beta
1.42
Analysts
Strong Buy
Price target
36.08 (+48.9%)
Earnings date
Nov 5, 2026

3M -5.85 (-19.38%)

202530Aug 13Sep 1Sep 21Oct 8Oct 2724.33

Key statistics

Enterprise value
2.55B
PEG ratio
3.45
Price / sales
0.52
Price / book
0.81
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
3.20%
Free cash flow
185.94M
Total cash
12.56M
Total debt
1.37B
Return on equity
-54.14%
Short % of float
24.18%
50-day average
19.90
200-day average
23.05

Financials — quick view

All financials
ENOV Revenue — quarterly 582.78M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ENOV Net income — quarterly -1.19M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ENOV EPS — quarterly -0.02
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ENOV recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Oct 3, 20260.767———
Aug 6, 2026Jul 3, 20260.8470.90+0.05+6.26%
May 7, 2026Apr 3, 20260.820.89+0.07+8.54%
Feb 26, 2026Dec 31, 20250.810.95+0.14+17.28%
Nov 6, 2025Oct 3, 20250.670.75+0.08+11.94%
Aug 7, 2025Jul 4, 20250.740.79+0.05+6.76%

Upgrades / downgrades

ENOV analyst upgrades and downgrades
DateFirmActionFromTo
Oct 12, 2026NeedhammainBuyBuy
Sep 2, 2026Wells FargomainOverweightOverweight
Sep 2, 2026CitizensmainMarket OutperformMarket Outperform
Sep 2, 2026Freedom Capital MarketsmainBuyBuy
Sep 1, 2026BTIGmainBuyBuy
Aug 17, 2026Canaccord GenuitymainBuyBuy

About Enovis Corporation

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
enovis.com

News

Your note

Sign in to keep a note on ENOV — it syncs with the Stock Master app.

Insider holders

ENOV insider holders
InsiderRelationLatest transactionDateShares held
BERRY PHILLIP BENJAMIN BENChief Financial OfficerStock Award(Grant)Mar 8, 2026158,596
ENGERT OLIVEROfficerPurchaseSep 3, 202663,898
LANG PATRICIA AOfficerStock Award(Grant)Mar 8, 202675,703
MCDONALD DAMIENChief Executive OfficerPurchaseSep 3, 2026247,077
PRYOR DANIEL ALEXISFormerSaleDec 8, 20250
ROSS TERRY DOfficerStock Award(Grant)Mar 8, 202668,477

Institution ownership

ENOV institution ownership
Holder% heldSharesValueReported
Blackrock Inc.17.85%10,295,666214.92MJun 29, 2026
American Century Companies Inc10.59%6,106,561127.47MJun 29, 2026
Vanguard Portfolio Management LLC6.81%3,926,26881.96MJun 29, 2026
Rubric Capital Management LP6.76%3,900,00081.41MJun 29, 2026
Vanguard Capital Management LLC4.31%2,484,31851.86MJun 29, 2026
State Street Corporation4.27%2,462,78851.41MJun 29, 2026

Fund ownership

ENOV fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.95%3,431,56971.63MSep 29, 2026
American Century Capital Portfolios, Inc.-Small Cap Value Fund4.54%2,620,00054.69MJun 29, 2026
American Century ETF Trust-Avantis U.S. Small Cap Value ETF3.80%2,189,18245.70MSep 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Value Fund3.52%2,032,40642.43MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.98%1,719,53035.90MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.59%1,493,64331.18MSep 29, 2026